Please note: This website includes an accessibility system. Press Control-F11 to adjust the website to the visually impaired who are using a screen reader; Press Control-F10 to open an accessibility menu.

Open accessibility options menu
  • 24/7
  • Buzz
  • Startups
  • VC
  • Finance@
  • Work@
  • Innovation
  • Opinions
  • Search
  • cleanSearch
  • Accesabillty
  • calcalist logo
bycalcalist logo
  • Homepage
  • Tags search
  • BiondVax

CTech 24/7

  • Economy under fire: Israel’s fiscal future hinges on war’s endgame
  • War with Iran? Tel Aviv Stock Exchange shrugs, rises for second day
  • “Outrageous and unprecedented”: Israel slams France over air show weapon ban
  • CTech's War Room: Live Log - June 16, 2025
More stories in CTech

BiondVax

2 stories about BiondVax
  • BiondVax's Ron Babecoff (left) and Tamar Ben-Yedidia. Photo: BiondVax

    Flu Season Might Soon Pass, for Good

    11.12.19|Lilach BaumerThe researchers behind Jerusalem-based BiondVax talked to Calcalist, discussing their potential universal flu vaccine, currently undergoing a phase 3 clinical trial

  • Marius Nacht. Photo: Orel Cohen

    Marius Nacht Buys Controlling Stake in Universal Flu Vaccine Developer BiondVax

    17.07.19|Micky GrunfeldBased in Jerusalem, Nasdaq-listed BiondVax develops a universal flu vaccine, currently in advanced clinical trials

Load more
Ctech Logo
Twitter
Twitter
Facebook
Facebook
NewsLetter
Newsletter
Contact Us
Contact Us
Rss
Rss
About CTech Terms of Use Privacy Policy
Developed by YIT UI & UX by Basch_Interactive